바로가기 및 건너띄기 링크: 본문 바로가기; 주메뉴 바로가기

글로벌제약산업정보

임상정보

국내 바이오의약품 임상 현황 (2022/2/7 ~ 2022/2/11)

국내 바이오의약품 임상 현황 (2022/2/7 ~ 2022/2/11) : 작성자, 작성일, 조회수, 출처,원문, 정보 제공
작성자	관리자
작성일	2022-02-15	조회수	1,225
국가정보	아시아>대한민국
출처	식품의약품안전처
원문	https://nedrug.mfds.go.kr/searchClinic

국내 바이오의약품 임상시험 현황입니다.

○기간: 2022.2.7. ~ 2022.2.11.

○출처: 의약품안전나라(의약품통합정보시스템) > 의약품등 정보 > 임상시험정보 > 임상시험정보공개 (링크 바로가기)

의뢰자	제품명	임상시험제목	임상시험 단계	개발지역	승인일
한국아이큐비아(주)	AMG 510	이전에 치료 받은 KRAS p.G12C 돌연변이가 있는 전이성 결장직장암 시험대상자의 치료를 위한 소토라십과 파니투무맙 대 시험자 선택 (트리플루리딘과 티피라실 또는 레고라페닙)의 제3상 다기관, 무작위 배정, 라벨 공개, 활성 대조 임상시험	3상	국외개발	2022-02-11
한국노바티스(주)	VAY736	활동성 루푸스 신염이 있는 참가자에서 표준 치료 요법에 추가한 이아날루맙의 유효성, 안전성 및 내약성을 평가하기 위한 무작위 배정, 이중 눈가림, 평행군, 위약 대조, 다기관 제 3 상 임상시험 (SIRIUS-LN)	3상	국외개발	2022-02-09
한국아스트라제네카(주)	더발루맙(durvalumab, MEDI4736)	국소국부 간세포암 환자를 대상으로 경동맥화학색전술(TACE)과 동시에 투여하는 Durvalumab+Tremelimumab±Lenvatinib 병용 요법을 TACE 단독치료와 비교 평가하는 제 III 상, 무작위배정, 공개라벨, 의뢰자 눈가림, 다기관 임상시험 (EMERALD-3)	3상	국외개발	2022-02-09
한국아이큐비아(주)	KER-050	골수섬유증 시험대상자에서 단독요법으로 투여하거나 룩소리티닙과 병용한 KER-050의 안전성, 내약성, 약동학 및 유효성을 평가하는 제2상 공개 시험	2상	국외개발	2022-02-09
한국애브비(주)	Epcoritamab	공격적인 재발성/불응성 성숙 B세포 신생물을 앓고 있는 소아 환자를 대상으로 한 Epcoritamab 단일군, 라벨 공개, 제1b상 임상시험	1b상	국외개발	2022-02-07
한국다이이찌산쿄 주식회사	DS-1062a (Datopotamab deruxtecan (Dato-DXd))	이전 치료 경험이 없고 조치 가능한 유전체 변이가 없는 진행성 또는 전이성 PD-L1 고발현(TPS≥50%) 비소세포폐암을 가진 시험대상자에서 Dato-DXd+펨브롤리주맙 대비 펨브롤리주맙 단독요법에 대한 무작위배정, 공개, 제 3상 임상시험 (Tropion Lung08)	3상	국외개발	2022-02-07
한국화이자제약(주)	PF-06863135	자가 조혈모세포 이식을 받은 후 미세잔존질환 양성인 새로 진단된 다발성 골수종 환자를 대상으로 한 레날리도마이드 대비 엘라나타맙(PF-06863135)의 무작위 배정, 2개군, 제3상 임상시험	3상	국외개발	2022-02-07
(주)에스엠티바이오	SMT-NK주	진행성 담도암 환자를 대상으로 SMT-NK주 (동종혈액유래 자연살해세포)/ 펨브롤리주맙 (Pembrolizumab) 병용요법과 펨브롤리주맙 (Pembrolizumab) 단독요법의 항종양활성을 비교평가 하기 위한 다기관, 무작위배정, 위약대조, 공개 제2b임상시험	2b상	국내개발	2022-02-07
피피디디벨럽먼트피티이엘티디	Cevostamab	재발성 또는 불응성 다발성 골수종 환자에서 피하 투여 세보스타맙(BFCR4350A)의 안전성, 약동학 및 활성을 평가하는 공개 라벨, 다기관, 제1b상 시험	1b상	국외개발	2022-02-07
한국아이큐비아(주)	BIIB059	비생물학적 루푸스 표준 치료를 배경 요법으로 받고 있는 성인 활성 전신 홍반성 루푸스 시험대상자에서 BIIB059의 유효성 및 안전성을 평가하기 위한 다기관, 무작위배정, 이중 눈가림, 위약대조, 3상 시험	3상	국외개발	2022-02-07

이전글 해외 바이오의약품 임상 현황 (2022/2/7 ~ 2022/2/13)
다음글 2021 임상시험 관련 자주 묻는 질의응답(의약품)

<p align="left" style="margin: 0px; padding: 0px; color: rgb(125, 125, 125); text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'Nanum Gothic'; font-size: 13px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; box-sizing: inherit; orphans: 2; widows: 2; background-color: rgb(255, 255, 255); font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-size-adjust: none;" 255,="" rgb(255,="" 13px;="" nanum="">국내 바이오의약품 임상시험 현황입니다.<span style="color: rgb(125, 125, 125); text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 나눔고딕, NanumGothic, sans-serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; box-sizing: inherit; orphans: 2; widows: 2; background-color: rgb(255, 255, 255); font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-size-adjust: none;"> 
 
 
<p style="margin: 0px; padding: 0px; color: rgb(125, 125, 125); text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'Nanum Gothic'; font-size: 13px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; box-sizing: inherit; orphans: 2; widows: 2; background-color: rgb(255, 255, 255); font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-size-adjust: none;" 255,="" rgb(255,="" 13px;="" nanum="">○기간: 2022.2.7. ~ 2022.2.11.
<p style="margin: 0px; padding: 0px; color: rgb(125, 125, 125); text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'Nanum Gothic'; font-size: 13px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; box-sizing: inherit; orphans: 2; widows: 2; background-color: rgb(255, 255, 255); font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-size-adjust: none;" 255,="" rgb(255,="" 13px;="" nanum="">○출처: 의약품안전나라(의약품통합정보시스템) > 의약품등 정보 > 임상시험정보 > 임상시험정보공개 (<a style="border: 0px currentColor; border-image: none; color: rgb(125, 125, 125); text-decoration: none; box-sizing: inherit; text-size-adjust: none;" href="https://nedrug.mfds.go.kr/searchClinic" target="_self">링크 바로가기</a>)
<p style="margin: 0px; padding: 0px; color: rgb(125, 125, 125); text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'Nanum Gothic'; font-size: 13px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; box-sizing: inherit; orphans: 2; widows: 2; background-color: rgb(255, 255, 255); font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-size-adjust: none;" 255,="" rgb(255,="" 13px;="" nanum=""> <span style="color: rgb(0, 0, 0); text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'Nanum Gothic'; font-size: 13px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; box-sizing: inherit; orphans: 2; widows: 2; background-color: rgb(255, 255, 255); font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-size-adjust: none;"> 
<table style="border: currentColor; border-image: none; border-collapse: collapse; table-layout: fixed; box-sizing: inherit; border-spacing: 0px; text-size-adjust: none;"> 
<tbody style="box-sizing: inherit; text-size-adjust: none;"> 
<tr style="box-sizing: inherit; text-size-adjust: none;"> 
<td valign="middle" style="background: rgb(242, 242, 242); margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 100.02pt; height: 34.31pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
의뢰자</td> 
<td valign="middle" style="background: rgb(242, 242, 242); margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 71.72pt; height: 34.31pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
제품명</td> 
<td valign="middle" style="background: rgb(242, 242, 242); margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 255.02pt; height: 34.31pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
임상시험제목</td> 
<td valign="middle" style="background: rgb(242, 242, 242); margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 68pt; height: 34.31pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
임상시험 단계</td> 
<td valign="middle" style="background: rgb(242, 242, 242); margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 51.17pt; height: 34.31pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
개발지역</td> 
<td valign="middle" style="background: rgb(242, 242, 242); margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 70.49pt; height: 34.31pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
승인일</td> 
</tr> 
<tr style="box-sizing: inherit; text-size-adjust: none;"> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 100.02pt; height: 81.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
한국아이큐비아(주)</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 71.72pt; height: 81.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
AMG 510</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 255.02pt; height: 81.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
이전에 치료 받은 KRAS p.G12C 돌연변이가 있는 전이성 결장직장암 시험대상자의 치료를 위한 소토라십과 파니투무맙 대 시험자 선택 (트리플루리딘과 티피라실 또는 레고라페닙)의 제3상 다기관, 무작위 배정, 라벨 공개, 활성 대조 임상시험</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 68pt; height: 81.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
3상</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 51.17pt; height: 81.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
국외개발</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 70.49pt; height: 81.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
2022-02-11</td> 
</tr> 
<tr style="box-sizing: inherit; text-size-adjust: none;"> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 100.02pt; height: 81.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
한국노바티스(주)</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 71.72pt; height: 81.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
VAY736</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 255.02pt; height: 81.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
활동성 루푸스 신염이 있는 참가자에서 표준 치료 요법에 추가한 이아날루맙의 유효성, 안전성 및 내약성을 평가하기 위한 무작위 배정, 이중 눈가림, 평행군, 위약 대조, 다기관 제 3 상 임상시험 (SIRIUS-LN)</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 68pt; height: 81.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
3상</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 51.17pt; height: 81.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
국외개발</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 70.49pt; height: 81.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
2022-02-09</td> 
</tr> 
<tr style="box-sizing: inherit; text-size-adjust: none;"> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 100.02pt; height: 94.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
한국아스트라제네카(주)</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 71.72pt; height: 94.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
더발루맙(durvalumab, MEDI4736)</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 255.02pt; height: 94.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
국소국부 간세포암 환자를 대상으로 경동맥화학색전술(TACE)과 동시에 투여하는 Durvalumab+Tremelimumab±Lenvatinib 병용 요법을 TACE 단독치료와 비교 평가하는 제 III 상, 무작위배정, 공개라벨, 의뢰자 눈가림, 다기관 임상시험 (EMERALD-3)</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 68pt; height: 94.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
3상</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 51.17pt; height: 94.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
국외개발</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 70.49pt; height: 94.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
2022-02-09</td> 
</tr> 
<tr style="box-sizing: inherit; text-size-adjust: none;"> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 100.02pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
한국아이큐비아(주)</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 71.72pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
KER-050</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 255.02pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
골수섬유증 시험대상자에서 단독요법으로 투여하거나 룩소리티닙과 병용한 KER-050의 안전성, 내약성, 약동학 및 유효성을 평가하는 제2상 공개 시험</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 68pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
2상</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 51.17pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
국외개발</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 70.49pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
2022-02-09</td> 
</tr> 
<tr style="box-sizing: inherit; text-size-adjust: none;"> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 100.02pt; height: 55.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
한국애브비(주)</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 71.72pt; height: 55.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
Epcoritamab</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 255.02pt; height: 55.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
공격적인 재발성/불응성 성숙 B세포 신생물을 앓고 있는 소아 환자를 대상으로 한 Epcoritamab 단일군, 라벨 공개, 제1b상 임상시험</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 68pt; height: 55.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
1b상</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 51.17pt; height: 55.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
국외개발</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 70.49pt; height: 55.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
2022-02-07</td> 
</tr> 
<tr style="box-sizing: inherit; text-size-adjust: none;"> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 100.02pt; height: 104.43pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
한국다이이찌산쿄 주식회사</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 71.72pt; height: 104.43pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
DS-1062a (Datopotamab deruxtecan (Dato-DXd))</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 255.02pt; height: 104.43pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
이전 치료 경험이 없고 조치 가능한 유전체 변이가 없는 진행성 또는 전이성 PD-L1 고발현(TPS≥50%) 비소세포폐암을 가진 시험대상자에서 Dato-DXd+펨브롤리주맙 대비 펨브롤리주맙 단독요법에 대한 무작위배정, 공개, 제 3상 임상시험 (Tropion Lung08)</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 68pt; height: 104.43pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
3상</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 51.17pt; height: 104.43pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
국외개발</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 70.49pt; height: 104.43pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
2022-02-07</td> 
</tr> 
<tr style="box-sizing: inherit; text-size-adjust: none;"> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 100.02pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
한국화이자제약(주)</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 71.72pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
PF-06863135</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 255.02pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
자가 조혈모세포 이식을 받은 후 미세잔존질환 양성인 새로 진단된 다발성 골수종 환자를 대상으로 한 레날리도마이드 대비 엘라나타맙(PF-06863135)의 무작위 배정, 2개군, 제3상 임상시험</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 68pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
3상</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 51.17pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
국외개발</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 70.49pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
2022-02-07</td> 
</tr> 
<tr style="box-sizing: inherit; text-size-adjust: none;"> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 100.02pt; height: 94.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
(주)에스엠티바이오</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 71.72pt; height: 94.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
SMT-NK주</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 255.02pt; height: 94.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
진행성 담도암 환자를 대상으로 SMT-NK주 (동종혈액유래 자연살해세포)/ 펨브롤리주맙 (Pembrolizumab) 병용요법과 펨브롤리주맙 (Pembrolizumab) 단독요법의 항종양활성을 비교평가 하기 위한 다기관, 무작위배정, 위약대조, 공개 제2b임상시험</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 68pt; height: 94.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
2b상</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 51.17pt; height: 94.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
국내개발</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 70.49pt; height: 94.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
2022-02-07</td> 
</tr> 
<tr style="box-sizing: inherit; text-size-adjust: none;"> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 100.02pt; height: 55.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
피피디디벨럽먼트피티이엘티디</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 71.72pt; height: 55.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
Cevostamab</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 255.02pt; height: 55.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
재발성 또는 불응성 다발성 골수종 환자에서 피하 투여 세보스타맙(BFCR4350A)의 안전성, 약동학 및 활성을 평가하는 공개 라벨, 다기관, 제1b상 시험</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 68pt; height: 55.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
1b상</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 51.17pt; height: 55.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
국외개발</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 70.49pt; height: 55.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
2022-02-07</td> 
</tr> 
<tr style="box-sizing: inherit; text-size-adjust: none;"> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 100.02pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
한국아이큐비아(주)</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 71.72pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
BIIB059</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 255.02pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
비생물학적 루푸스 표준 치료를 배경 요법으로 받고 있는 성인 활성 전신 홍반성 루푸스 시험대상자에서 BIIB059의 유효성 및 안전성을 평가하기 위한 다기관, 무작위배정, 이중 눈가림, 위약대조, 3상 시험</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 68pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
3상</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 51.17pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
국외개발</td> 
<td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 70.49pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;">
2022-02-07</td> 
</tr> 
</tbody> 
</table>

<p align="left" style="margin: 0px; padding: 0px; color: rgb(125, 125, 125); text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'Nanum Gothic'; font-size: 13px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; box-sizing: inherit; orphans: 2; widows: 2; background-color: rgb(255, 255, 255); font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-size-adjust: none;" 255,="" rgb(255,="" 13px;="" nanum="">국내 바이오의약품 임상시험 현황입니다.<span style="color: rgb(125, 125, 125); text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 나눔고딕, NanumGothic, sans-serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; box-sizing: inherit; orphans: 2; widows: 2; background-color: rgb(255, 255, 255); font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-size-adjust: none;"> <p style="margin: 0px; padding: 0px; color: rgb(125, 125, 125); text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'Nanum Gothic'; font-size: 13px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; box-sizing: inherit; orphans: 2; widows: 2; background-color: rgb(255, 255, 255); font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-size-adjust: none;" 255,="" rgb(255,="" 13px;="" nanum="">○기간: 2022.2.7. ~ 2022.2.11. <p style="margin: 0px; padding: 0px; color: rgb(125, 125, 125); text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'Nanum Gothic'; font-size: 13px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; box-sizing: inherit; orphans: 2; widows: 2; background-color: rgb(255, 255, 255); font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-size-adjust: none;" 255,="" rgb(255,="" 13px;="" nanum="">○출처: 의약품안전나라(의약품통합정보시스템) > 의약품등 정보 > 임상시험정보 > 임상시험정보공개 (<a style="border: 0px currentColor; border-image: none; color: rgb(125, 125, 125); text-decoration: none; box-sizing: inherit; text-size-adjust: none;" href="https://nedrug.mfds.go.kr/searchClinic" target="_self">링크 바로가기</a>) <p style="margin: 0px; padding: 0px; color: rgb(125, 125, 125); text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'Nanum Gothic'; font-size: 13px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; box-sizing: inherit; orphans: 2; widows: 2; background-color: rgb(255, 255, 255); font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-size-adjust: none;" 255,="" rgb(255,="" 13px;="" nanum=""> <span style="color: rgb(0, 0, 0); text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'Nanum Gothic'; font-size: 13px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; box-sizing: inherit; orphans: 2; widows: 2; background-color: rgb(255, 255, 255); font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-size-adjust: none;"> <table style="border: currentColor; border-image: none; border-collapse: collapse; table-layout: fixed; box-sizing: inherit; border-spacing: 0px; text-size-adjust: none;"> <tbody style="box-sizing: inherit; text-size-adjust: none;"> <tr style="box-sizing: inherit; text-size-adjust: none;"> <td valign="middle" style="background: rgb(242, 242, 242); margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 100.02pt; height: 34.31pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 의뢰자</td> <td valign="middle" style="background: rgb(242, 242, 242); margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 71.72pt; height: 34.31pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 제품명</td> <td valign="middle" style="background: rgb(242, 242, 242); margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 255.02pt; height: 34.31pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 임상시험제목</td> <td valign="middle" style="background: rgb(242, 242, 242); margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 68pt; height: 34.31pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 임상시험 단계</td> <td valign="middle" style="background: rgb(242, 242, 242); margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 51.17pt; height: 34.31pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 개발지역</td> <td valign="middle" style="background: rgb(242, 242, 242); margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 70.49pt; height: 34.31pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 승인일</td> </tr> <tr style="box-sizing: inherit; text-size-adjust: none;"> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 100.02pt; height: 81.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 한국아이큐비아(주)</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 71.72pt; height: 81.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> AMG 510</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 255.02pt; height: 81.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 이전에 치료 받은 KRAS p.G12C 돌연변이가 있는 전이성 결장직장암 시험대상자의 치료를 위한 소토라십과 파니투무맙 대 시험자 선택 (트리플루리딘과 티피라실 또는 레고라페닙)의 제3상 다기관, 무작위 배정, 라벨 공개, 활성 대조 임상시험</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 68pt; height: 81.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 3상</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 51.17pt; height: 81.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 국외개발</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 70.49pt; height: 81.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 2022-02-11</td> </tr> <tr style="box-sizing: inherit; text-size-adjust: none;"> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 100.02pt; height: 81.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 한국노바티스(주)</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 71.72pt; height: 81.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> VAY736</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 255.02pt; height: 81.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 활동성 루푸스 신염이 있는 참가자에서 표준 치료 요법에 추가한 이아날루맙의 유효성, 안전성 및 내약성을 평가하기 위한 무작위 배정, 이중 눈가림, 평행군, 위약 대조, 다기관 제 3 상 임상시험 (SIRIUS-LN)</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 68pt; height: 81.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 3상</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 51.17pt; height: 81.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 국외개발</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 70.49pt; height: 81.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 2022-02-09</td> </tr> <tr style="box-sizing: inherit; text-size-adjust: none;"> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 100.02pt; height: 94.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 한국아스트라제네카(주)</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 71.72pt; height: 94.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 더발루맙(durvalumab, MEDI4736)</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 255.02pt; height: 94.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 국소국부 간세포암 환자를 대상으로 경동맥화학색전술(TACE)과 동시에 투여하는 Durvalumab+Tremelimumab±Lenvatinib 병용 요법을 TACE 단독치료와 비교 평가하는 제 III 상, 무작위배정, 공개라벨, 의뢰자 눈가림, 다기관 임상시험 (EMERALD-3)</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 68pt; height: 94.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 3상</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 51.17pt; height: 94.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 국외개발</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 70.49pt; height: 94.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 2022-02-09</td> </tr> <tr style="box-sizing: inherit; text-size-adjust: none;"> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 100.02pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 한국아이큐비아(주)</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 71.72pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> KER-050</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 255.02pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 골수섬유증 시험대상자에서 단독요법으로 투여하거나 룩소리티닙과 병용한 KER-050의 안전성, 내약성, 약동학 및 유효성을 평가하는 제2상 공개 시험</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 68pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 2상</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 51.17pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 국외개발</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 70.49pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 2022-02-09</td> </tr> <tr style="box-sizing: inherit; text-size-adjust: none;"> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 100.02pt; height: 55.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 한국애브비(주)</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 71.72pt; height: 55.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> Epcoritamab</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 255.02pt; height: 55.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 공격적인 재발성/불응성 성숙 B세포 신생물을 앓고 있는 소아 환자를 대상으로 한 Epcoritamab 단일군, 라벨 공개, 제1b상 임상시험</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 68pt; height: 55.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 1b상</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 51.17pt; height: 55.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 국외개발</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 70.49pt; height: 55.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 2022-02-07</td> </tr> <tr style="box-sizing: inherit; text-size-adjust: none;"> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 100.02pt; height: 104.43pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 한국다이이찌산쿄 주식회사</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 71.72pt; height: 104.43pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> DS-1062a (Datopotamab deruxtecan (Dato-DXd))</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 255.02pt; height: 104.43pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 이전 치료 경험이 없고 조치 가능한 유전체 변이가 없는 진행성 또는 전이성 PD-L1 고발현(TPS≥50%) 비소세포폐암을 가진 시험대상자에서 Dato-DXd+펨브롤리주맙 대비 펨브롤리주맙 단독요법에 대한 무작위배정, 공개, 제 3상 임상시험 (Tropion Lung08)</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 68pt; height: 104.43pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 3상</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 51.17pt; height: 104.43pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 국외개발</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 70.49pt; height: 104.43pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 2022-02-07</td> </tr> <tr style="box-sizing: inherit; text-size-adjust: none;"> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 100.02pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 한국화이자제약(주)</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 71.72pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> PF-06863135</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 255.02pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 자가 조혈모세포 이식을 받은 후 미세잔존질환 양성인 새로 진단된 다발성 골수종 환자를 대상으로 한 레날리도마이드 대비 엘라나타맙(PF-06863135)의 무작위 배정, 2개군, 제3상 임상시험</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 68pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 3상</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 51.17pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 국외개발</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 70.49pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 2022-02-07</td> </tr> <tr style="box-sizing: inherit; text-size-adjust: none;"> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 100.02pt; height: 94.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> (주)에스엠티바이오</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 71.72pt; height: 94.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> SMT-NK주</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 255.02pt; height: 94.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 진행성 담도암 환자를 대상으로 SMT-NK주 (동종혈액유래 자연살해세포)/ 펨브롤리주맙 (Pembrolizumab) 병용요법과 펨브롤리주맙 (Pembrolizumab) 단독요법의 항종양활성을 비교평가 하기 위한 다기관, 무작위배정, 위약대조, 공개 제2b임상시험</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 68pt; height: 94.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 2b상</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 51.17pt; height: 94.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 국내개발</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 70.49pt; height: 94.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 2022-02-07</td> </tr> <tr style="box-sizing: inherit; text-size-adjust: none;"> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 100.02pt; height: 55.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 피피디디벨럽먼트피티이엘티디</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 71.72pt; height: 55.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> Cevostamab</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 255.02pt; height: 55.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 재발성 또는 불응성 다발성 골수종 환자에서 피하 투여 세보스타맙(BFCR4350A)의 안전성, 약동학 및 활성을 평가하는 공개 라벨, 다기관, 제1b상 시험</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 68pt; height: 55.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 1b상</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 51.17pt; height: 55.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 국외개발</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 70.49pt; height: 55.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 2022-02-07</td> </tr> <tr style="box-sizing: inherit; text-size-adjust: none;"> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 100.02pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 한국아이큐비아(주)</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 71.72pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> BIIB059</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 255.02pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 비생물학적 루푸스 표준 치료를 배경 요법으로 받고 있는 성인 활성 전신 홍반성 루푸스 시험대상자에서 BIIB059의 유효성 및 안전성을 평가하기 위한 다기관, 무작위배정, 이중 눈가림, 위약대조, 3상 시험</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 68pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 3상</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 51.17pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 국외개발</td> <td valign="middle" style="margin: 0px; padding: 0px; border: 1px solid rgb(166, 166, 166); border-image: none; width: 70.49pt; height: 68.8pt; color: rgb(125, 125, 125); line-height: 1.6; font-family: 'Nanum Gothic'; font-size: 13px; box-sizing: inherit; text-size-adjust: none;"> 2022-02-07</td> </tr> </tbody> </table> 
소스입니다. Ctrl+C를 눌러 클립보드로 복사하세요

제약산업정보포털

인기검색어 TOP 10

전체메뉴

글로벌제약산업정보

임상정보

국내 바이오의약품 임상 현황 (2022/2/7 ~ 2022/2/11)

관련기관 배너모음